Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Regimen-stratified genomics identifies candidate markers of benefit and resistance in adult T-cell leukemia/lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXiaoyi ZhangKSKimberly Seymour

Discussion

Loading...

Member takes

Overview

Genomic analysis identifies resistance and benefit markers in adult T-cell leukemia/lymphoma, suggesting potential for personalized treatment strategies.

Key Points

  • Resistance markers included IRF4 and CARD11, associated with significantly shorter progression-free survival.
  • Next-generation sequencing revealed actionable sensitivity markers such as DIS3 and ARID1B with notable positive outcomes.
  • Exploratory analysis showed 36 significant single-gene associations across treatment regimens in adult T-cell leukemia/lymphoma.
  • Findings emphasize the need for genomics-guided regimens to enhance treatment personalization and effectiveness.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d56dhttps://doi.org/10.1182/blood-2025-7059
View Full Paper
Ask AI
Bookmark
Share